Placeholder Banner

BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency Bill

October 9, 2017

Washington, D.C. (October 9, 2017) – Biotechnology Innovation Organization (BIO) Senior Executive Vice President for Public Affairs Gary Andres issued the following statement following California Governor Jerry Brown’s signing of the drug price reporting and transparency bill Senate Bill 17 into law:

“As the world’s leader in biopharmaceutical innovation, California is home to over 2,800 companies that employ a workforce of over 242,000 dedicated men and women focused on innovative solutions to improving human health and increased patient access to breakthrough medicines.

“The legislation the Governor signed into law seriously jeopardizes the future of California’s leadership in this innovative industry. Despite its intent, this law will neither provide meaningful information to patients nor lower prescription drug costs.

“By ignoring the realities of biopharmaceutical development, Senate Bill 17 will delay or prevent future biopharmaceutical innovation by driving investment toward other industry sectors that are not burdened with this type of misguided government intrusion.”

###

Discover More
Washington, D.C. (October 3, 2022) – Today, a coalition of leading food and agriculture industry stakeholders in both Mexico and the United States released a new study revealing the broad impacts of Mexico’s proposed ban on biotech corn. The report,…
Biotechnology Industry Organization (BIO) President and CEO, Dr. Michelle McMurry-Heath, released the following statement following the announcement that Congress reached an agreement on the Prescription Drug User Fee Act (PDUFA): “For 30…
Dr. Michelle McMurry-Heath, president & CEO of the Biotechnology Innovation Organization, released the following statement in response to the Biden Administration’s “Advancing Biotechnology and Biomanufacturing” Executive Order: “BIO welcomes…